Ultra Nasdaq Biotechnology 2X ETF (BIB)

N/A +N/A (N/A)
Market Cap N/A
Revenue (ttm) N/A
Net Income (ttm) N/A
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume N/A
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts N/A
Price Target N/A

Company Profile

The index is designed to measure the performance of a set of Nasdaq-listed biotechnology and pharmaceutical companies. Under normal circumstances, the fund will obtain leveraged exposure to at least 80% of its total assets in components of the index or in instruments with similar economic characteristics. The fund is non-diversified.

macrossluvsrobotech
macrossluvsrobotech Jul. 31 at 5:00 PM
$LXRX + $NVO ABC News reports the VA is running a major trial using GLP‑1 drugs to treat alcohol-use disorder — showing GLP‑1s don’t just curb appetite, they modulate reward circuits and compulsive drive. This is quietly bullish for LXRX. As GLP‑1s expand beyond weight loss into addiction therapy, exposure rises — and so do catabolic side effects like rapid fat-pad loss and lean-mass depletion. That’s where LX9851 + ACSL blockade fits. ACSL blockers modulate lipid flux, preserve lean mass, and protect structural fat compartments. If GLP‑1s become a multi- indication platform (obesity, diabetes, addiction), LX9851 becomes a companion therapy that improves tolerability and broadens use. Novo Nordisk is already partnered with LXRX. GLP‑1 expansion = LX9851 opportunity. $BIB $VTRS https://www.foxnews.com/video/6402530344112 https://www.militarytimes.com/veterans/2026/07/30/va-launches-trial-to-test-glp-1-medication-for-alcohol-use-disorder-in-veterans/
1 · Reply
macrossluvsrobotech
macrossluvsrobotech Jul. 31 at 4:58 PM
$LXRX + $NVO USA Today reports a new GLP‑1 side effect: temporal hollowing — sunken temples caused by rapid loss of subcutaneous fat. This isn’t muscle loss; the article makes clear it’s compartment‑specific fat depletion in one of the thinnest facial fat pads. When GLP‑1 weight loss outpaces tissue remodeling, the temples collapse, creating the “suddenly older” look now going viral. This matters for biotech: it shows how GLP‑1s can strip fat from sensitive regions that were never meant to lose volume quickly. That’s exactly where LXRX’s LX9851 + ACSL blocker concept shines — targeted lipid‑flux modulation designed to preserve structural fat compartments while still driving metabolic benefit. Temporal hollowing = proof that precision fat‑handling drugs are the next frontier. $BIB $VTRS https://www.usatoday.com/story/life/health-wellness/2026/07/31/ozempic-temporal-hollowing/91113282007/
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Jul. 24 at 9:57 PM
$LXRX + $NVO ( $LLY ) $BIB $VTRS = LX9851 ACSL blockers like ACSL inhibition (LX9851 from Lexicon Pharmaceuticals, Inc. ) offer an intriguing angle on GLP‑1 side effects because they modulate gut‑hormone release indirectly rather than flooding the system with injected GLP‑1 agonists. By activating the ileal brake, ACSL blockers may promote steadier appetite reduction and slower metabolic shifts. That matters because GLP‑1‑related hair loss is often driven by rapid weight‑loss stress (telogen effluvium), and “Ozempic face” stems from abrupt subcutaneous fat loss. If ACSL blockers support more gradual fat reduction and better lean‑mass preservation, bone preservation, they could theoretically soften these effects. Evidence is still early, but the mechanism suggests a pathway toward gentler_weight_loss with fewer aesthetic downsides.
0 · Reply
jjon2121
jjon2121 Jul. 7 at 12:51 PM
$LABD $LABU $BIB $IBB$XBI Reason bio pumping again. Announced Vertex buying Crinetics for $10B Announced yesterday. https://www.bioworld.com/articles/732285-novartis-to-pay-15b-for-myricx-bio-and-its-novel-adc-payloads As long as these buyouts keep coming, bio won't stop. Big difference between now & previous years. Companies would never announce buyouts with prices this high before. They would wait for pullback to get a better price & runup.
4 · Reply
macrossluvsrobotech
macrossluvsrobotech Jun. 29 at 4:28 PM
$LXRX Aaaand there's this **NEWS JUST OUT**= VERY VERY BIG (In my view) = STARTING TOMORROW JULY 1st = GLP -1 's now covered by Medicare The Medicare GLP-1 Bridge Program is scheduled to last for exactly 18 months, running from July 1, 2026, through December 31, 2027.Because this is launched as a federal demonstration pilot rather than a permanent change to the law, the program will automatically expire at the end of 2027 unless Congress passes new legislation to permanently overturn the decades-old ban on Medicare weight-loss coverage. Because federal law explicitly bans Medicare from covering weight-loss drugs, the current 18-month program is a loophole called a "demonstration project." The executive branch uses these projects to test new coverage rules temporarily, but they cannot keep them going indefinitely without a legislative change. https://www.medicare.gov/coverage/weight-loss-drugs $VRTS $NVO $LLY $BIB
0 · Reply
howardlindzon
howardlindzon Jun. 29 at 1:28 PM
the case for biotech and the breakout good read $XBI $BIB $IBB $XLV https://thierryvonarvy.substack.com/p/the-biotech-breakout
1 · Reply
Scatpack22
Scatpack22 Jun. 27 at 6:52 PM
$BIB Who bought that breakout at $91 other than me?
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Jun. 11 at 1:28 PM
$BIB $LXRX $NVO $VTRS 🇯🇵 Since 2018, Japan has approved Suglat (ipragliflozin) as an insulin add-on for T1D — first SGLT2i cleared there. A patient satisfaction survey (DTSQ) showed real QoL gains: better glucose control, lower insulin needs. 🇺🇸 Sotagliflozin (Zynquista— same dual SGLT1/2 class — showed comparable benefits in inTandem trials: lower A1C, reduced bodyweight, less insulin required, sustained over 52 weeks. FDA gave feedback that the STENO1 study (Steno Diabetes Center) is adequately designed to provide DKA safety data supporting an NDA resubmission, with potential 2026 approval if requirements are met. STENO1 is past 50% enrollment, completing mid-2026 Breakthrough T1D backed early Zynquista trials citing significant blood-sugar reduction. Dr. Steve Edelman (UCSD/TCOYD) testified insulin alone isn’t enough for many T1D patients. =fewer/smaller insulin shots, tighter glucose control, better daily QoL — echoing what Japan’s T1D patients have reported since 2018.
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Jun. 11 at 1:26 PM
$BIB $LXRX $NVO $VTRS This cerebras expert is now a Lexicon Pharma Expert. Cute.
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Jun. 11 at 1:25 PM
$BIB $LXRX $NVO $VTRS YOU FOOL. EVERYBODY KNOWS YOU STILL NEED INSULIN. ONLY AN IDIOT WOULD BELIEVE OTHERWISE. A POST THAT EMPHASIZES THE BENEFITS OF A PILL OVER PUMPING INSULIN ARE IRREFUTABLE LIKE THAT HAVE BEEN IN JAPAN SINCE 2019.
0 · Reply
Latest News on BIB
Here is a List of Small-Cap Biotech ETFs to Watch for Big Gains in 2026

2026-02-19T19:18:15.000Z - 5 months ago

Here is a List of Small-Cap Biotech ETFs to Watch for Big Gains in 2026

CRBU CRNX GNOM HRTS REGN VKTX VRTX

macrossluvsrobotech
macrossluvsrobotech Jul. 31 at 5:00 PM
$LXRX + $NVO ABC News reports the VA is running a major trial using GLP‑1 drugs to treat alcohol-use disorder — showing GLP‑1s don’t just curb appetite, they modulate reward circuits and compulsive drive. This is quietly bullish for LXRX. As GLP‑1s expand beyond weight loss into addiction therapy, exposure rises — and so do catabolic side effects like rapid fat-pad loss and lean-mass depletion. That’s where LX9851 + ACSL blockade fits. ACSL blockers modulate lipid flux, preserve lean mass, and protect structural fat compartments. If GLP‑1s become a multi- indication platform (obesity, diabetes, addiction), LX9851 becomes a companion therapy that improves tolerability and broadens use. Novo Nordisk is already partnered with LXRX. GLP‑1 expansion = LX9851 opportunity. $BIB $VTRS https://www.foxnews.com/video/6402530344112 https://www.militarytimes.com/veterans/2026/07/30/va-launches-trial-to-test-glp-1-medication-for-alcohol-use-disorder-in-veterans/
1 · Reply
macrossluvsrobotech
macrossluvsrobotech Jul. 31 at 4:58 PM
$LXRX + $NVO USA Today reports a new GLP‑1 side effect: temporal hollowing — sunken temples caused by rapid loss of subcutaneous fat. This isn’t muscle loss; the article makes clear it’s compartment‑specific fat depletion in one of the thinnest facial fat pads. When GLP‑1 weight loss outpaces tissue remodeling, the temples collapse, creating the “suddenly older” look now going viral. This matters for biotech: it shows how GLP‑1s can strip fat from sensitive regions that were never meant to lose volume quickly. That’s exactly where LXRX’s LX9851 + ACSL blocker concept shines — targeted lipid‑flux modulation designed to preserve structural fat compartments while still driving metabolic benefit. Temporal hollowing = proof that precision fat‑handling drugs are the next frontier. $BIB $VTRS https://www.usatoday.com/story/life/health-wellness/2026/07/31/ozempic-temporal-hollowing/91113282007/
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Jul. 24 at 9:57 PM
$LXRX + $NVO ( $LLY ) $BIB $VTRS = LX9851 ACSL blockers like ACSL inhibition (LX9851 from Lexicon Pharmaceuticals, Inc. ) offer an intriguing angle on GLP‑1 side effects because they modulate gut‑hormone release indirectly rather than flooding the system with injected GLP‑1 agonists. By activating the ileal brake, ACSL blockers may promote steadier appetite reduction and slower metabolic shifts. That matters because GLP‑1‑related hair loss is often driven by rapid weight‑loss stress (telogen effluvium), and “Ozempic face” stems from abrupt subcutaneous fat loss. If ACSL blockers support more gradual fat reduction and better lean‑mass preservation, bone preservation, they could theoretically soften these effects. Evidence is still early, but the mechanism suggests a pathway toward gentler_weight_loss with fewer aesthetic downsides.
0 · Reply
jjon2121
jjon2121 Jul. 7 at 12:51 PM
$LABD $LABU $BIB $IBB$XBI Reason bio pumping again. Announced Vertex buying Crinetics for $10B Announced yesterday. https://www.bioworld.com/articles/732285-novartis-to-pay-15b-for-myricx-bio-and-its-novel-adc-payloads As long as these buyouts keep coming, bio won't stop. Big difference between now & previous years. Companies would never announce buyouts with prices this high before. They would wait for pullback to get a better price & runup.
4 · Reply
macrossluvsrobotech
macrossluvsrobotech Jun. 29 at 4:28 PM
$LXRX Aaaand there's this **NEWS JUST OUT**= VERY VERY BIG (In my view) = STARTING TOMORROW JULY 1st = GLP -1 's now covered by Medicare The Medicare GLP-1 Bridge Program is scheduled to last for exactly 18 months, running from July 1, 2026, through December 31, 2027.Because this is launched as a federal demonstration pilot rather than a permanent change to the law, the program will automatically expire at the end of 2027 unless Congress passes new legislation to permanently overturn the decades-old ban on Medicare weight-loss coverage. Because federal law explicitly bans Medicare from covering weight-loss drugs, the current 18-month program is a loophole called a "demonstration project." The executive branch uses these projects to test new coverage rules temporarily, but they cannot keep them going indefinitely without a legislative change. https://www.medicare.gov/coverage/weight-loss-drugs $VRTS $NVO $LLY $BIB
0 · Reply
howardlindzon
howardlindzon Jun. 29 at 1:28 PM
the case for biotech and the breakout good read $XBI $BIB $IBB $XLV https://thierryvonarvy.substack.com/p/the-biotech-breakout
1 · Reply
Scatpack22
Scatpack22 Jun. 27 at 6:52 PM
$BIB Who bought that breakout at $91 other than me?
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Jun. 11 at 1:28 PM
$BIB $LXRX $NVO $VTRS 🇯🇵 Since 2018, Japan has approved Suglat (ipragliflozin) as an insulin add-on for T1D — first SGLT2i cleared there. A patient satisfaction survey (DTSQ) showed real QoL gains: better glucose control, lower insulin needs. 🇺🇸 Sotagliflozin (Zynquista— same dual SGLT1/2 class — showed comparable benefits in inTandem trials: lower A1C, reduced bodyweight, less insulin required, sustained over 52 weeks. FDA gave feedback that the STENO1 study (Steno Diabetes Center) is adequately designed to provide DKA safety data supporting an NDA resubmission, with potential 2026 approval if requirements are met. STENO1 is past 50% enrollment, completing mid-2026 Breakthrough T1D backed early Zynquista trials citing significant blood-sugar reduction. Dr. Steve Edelman (UCSD/TCOYD) testified insulin alone isn’t enough for many T1D patients. =fewer/smaller insulin shots, tighter glucose control, better daily QoL — echoing what Japan’s T1D patients have reported since 2018.
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Jun. 11 at 1:26 PM
$BIB $LXRX $NVO $VTRS This cerebras expert is now a Lexicon Pharma Expert. Cute.
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Jun. 11 at 1:25 PM
$BIB $LXRX $NVO $VTRS YOU FOOL. EVERYBODY KNOWS YOU STILL NEED INSULIN. ONLY AN IDIOT WOULD BELIEVE OTHERWISE. A POST THAT EMPHASIZES THE BENEFITS OF A PILL OVER PUMPING INSULIN ARE IRREFUTABLE LIKE THAT HAVE BEEN IN JAPAN SINCE 2019.
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Jun. 11 at 1:02 AM
$LXRX = FDA DECISION COMING SHORTLY!! NO MORE PAINFUL INSULIN SHOTS FOR TYPE 1 Diabetes!!! FIRST ORAL PILL EVER!!!!! 💪😉🇺🇸🙏 $BIB partners = $NVO and $VTRS
2 · Reply
macrossluvsrobotech
macrossluvsrobotech Jun. 11 at 12:55 AM
$LXRX 💪😉 $BIB $UNH our partners = $NVO $VTRS
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Jun. 10 at 11:17 PM
$LXRX Type 1 DIABETES = ABOUT TO GET PAWNED. $BIB $UNH Our partners = $NVO $VTRS
0 · Reply
jjon2121
jjon2121 Jun. 10 at 1:39 PM
$LABU $LABD $XBI $IBB $BIB Go bulls. Buyout boost vs CPI.
0 · Reply
jjon2121
jjon2121 Jun. 9 at 9:41 AM
$LABU $LABD $XBI $IBB $BIB 3 bio buyouts. Incyte/Vega 2B. J&J/Firefly Bio 1B.. GSK/Nuvalent 10.6B That is 13.6B in buyouts. XBI 138. Here we come again. https://www.bioworld.com/articles/731689-incyte-nabs-potential-vwd-game-changer-in-vega-deal-j-and-j-buys-firefly https://www.fiercebiotech.com/biotech/gsk-inks-10.6b-nuvalent-buyout-challenge-roche-and-pfizer-lung-cancer
2 · Reply
MacroHard26
MacroHard26 Jun. 8 at 1:13 PM
$RVMD $XBI $LABU $BIB $SPY Revolutions $RVMD Daraxorasib alone or in combination with others in pancreatic cancer improved survival rates drastically. Tango plans to test the vopimetostat-daraxonrasib combination in first-line pancreatic cancer patients with a genetic mutation known as MTAP deletion, pending discussions with regulators. On going studies showing similar results in Lung and Rectal cancers.
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Jun. 6 at 1:30 PM
$CMPS The Michigan House Families and Veterans Committee held a hearing on a bill to create an ibogaine grant program to support research on whether the psychedelic is effective in treating substance use disorder and other mental health conditions—using $50 million in opioid settlement funds. https://x.com/tomangell/status/2063242961844883492?s=46 $BIB
0 · Reply
MacroHard26
MacroHard26 Jun. 5 at 4:15 AM
$RVMD $SPY $BIB $LABU $XBI https://www.streetwisereports.com/article/2026/06/04/california-pharma-co-tests-breakthrough-cancer-drug-cuts-death-risk-60.html
1 · Reply
macrossluvsrobotech
macrossluvsrobotech Jun. 4 at 8:49 PM
$LXRX 🚨 NEVER-BEFORE-SEEN DATA drops Sunday June 7 at ADA 2026. Pilavapadin Phase 1 renal PK study — first public presentation ever. Here's why this is HUGE: → DPNP patients almost universally have damaged kidneys (diabetes destroys them) → Every current pain drug — pregabalin, duloxetine, gabapentin — requires dose adjustments in kidney disease, creating prescribing nightmares → Pilavapadin? Renal function does NOT affect how this drug behaves in the body → No dose adjustment. No renal testing. Prescribe to virtually the entire DPNP population cleanly This removes the #1 real-world barrier to a new DPNP drug getting prescribed broadly. Clean FDA label. Massive commercial upside. Active partnership talks ongoing. Non-opioid. CNS-penetrant. Novel AAK1 mechanism. Presented by Dr. Rodica Pop-Busui — OHSU — independent world-class DPNP researcher. Not a Lexicon employee. NDA resubmission for sotagliflozin T1D also imminent — mid-2026. Two pipeline drugs. ~$245M market cap $BIB $VTRS $NVO
0 · Reply
MacroHard26
MacroHard26 Jun. 3 at 12:29 AM
$RVMD $LABU $XBI $BIB $SPY Revolution Medicines, Inc. has delivered unprecedented Phase 3 data for daraxonrasib in second-line metastatic pancreatic cancer, nearly doubling overall survival versus chemotherapy. RVMD's daraxonrasib reduced death risk by 60%, with a median OS of 13.2 months versus 6.6 months for chemotherapy, and showed a favorable safety profile. There is a strong clinical results and potential for $5BN+ peak PDAC revenues . In the overall population, the objective response rate was 31.6% with daraxonrasib compared with 11.2% for chemotherapy. Daraxonrasib reduced the risk of death by 60% compared with chemotherapy. No prior Phase III study in metastatic pancreatic cancer has demonstrated median overall survival exceeding 1 year in any line of therapy
0 · Reply
MacroHard26
MacroHard26 Jun. 2 at 2:53 PM
$RVMD $SPYD $BIB $XBI $RVMD https://youtu.be/d7NqRRbISBs?si=-XmyC_VGdJVfopqq
1 · Reply